Abstract
In this article we review the role of vascular endothelial growth factor (VEGF) in colon cancer growth and the underlying mechanisms. Angiogenesis, the growth of new capillary blood vessels in the body, is critical for tissue injury healing and cancer growth. In 1971, Judah Folkman proposed the concept that tumor growth beyond 2 mm is critically dependent on angiogenesis. Tumors including colon cancers release angiogenic growth factors that stimulate blood vessels to grow into the tumors thus providing oxygen and nutrients that enable exponential growth. VEGF is the most potent angiogenic growth factor. Several studies have highlighted the role of VEGF in colon cancer, specifically in the stimulation of angiogenesis. This role of VEGF is strongly supported by studies showing that inhibition of VEGF using the blocking antibody, bevacizumab, results in decreased angiogenesis and abrogation of cancer growth. In the United States, bevacizumab in combination with chemotherapy is FDA approved for the treatment of metastatic colon cancer. However, the source of VEGF in colon cancer tissue, the mechanisms of VEGF generation in colon cancer cells and the molecular pathways involved in VEGF mediated angiogenesis in colon cancer are not fully known. The possibility that VEGF directly stimulates cancer cell growth in an autocrine manner has not been explored in depth.
Keywords: Colon cancer, VEGF, angiogenesis, cancer cell growth.
Current Pharmaceutical Design
Title:VEGF and Colon Cancer Growth Beyond Angiogenesis: Does VEGF Directly Mediate Colon Cancer Growth Via a Non-angiogenic Mechanism?
Volume: 20 Issue: 7
Author(s): Amrita Ahluwalia, Michael K. Jones, Tamara Matysiak-Budnik and Andrzej S. Tarnawski
Affiliation:
Keywords: Colon cancer, VEGF, angiogenesis, cancer cell growth.
Abstract: In this article we review the role of vascular endothelial growth factor (VEGF) in colon cancer growth and the underlying mechanisms. Angiogenesis, the growth of new capillary blood vessels in the body, is critical for tissue injury healing and cancer growth. In 1971, Judah Folkman proposed the concept that tumor growth beyond 2 mm is critically dependent on angiogenesis. Tumors including colon cancers release angiogenic growth factors that stimulate blood vessels to grow into the tumors thus providing oxygen and nutrients that enable exponential growth. VEGF is the most potent angiogenic growth factor. Several studies have highlighted the role of VEGF in colon cancer, specifically in the stimulation of angiogenesis. This role of VEGF is strongly supported by studies showing that inhibition of VEGF using the blocking antibody, bevacizumab, results in decreased angiogenesis and abrogation of cancer growth. In the United States, bevacizumab in combination with chemotherapy is FDA approved for the treatment of metastatic colon cancer. However, the source of VEGF in colon cancer tissue, the mechanisms of VEGF generation in colon cancer cells and the molecular pathways involved in VEGF mediated angiogenesis in colon cancer are not fully known. The possibility that VEGF directly stimulates cancer cell growth in an autocrine manner has not been explored in depth.
Export Options
About this article
Cite this article as:
Ahluwalia Amrita, Jones K. Michael, Matysiak-Budnik Tamara and Tarnawski S. Andrzej, VEGF and Colon Cancer Growth Beyond Angiogenesis: Does VEGF Directly Mediate Colon Cancer Growth Via a Non-angiogenic Mechanism?, Current Pharmaceutical Design 2014; 20 (7) . https://dx.doi.org/10.2174/1381612819999131218175905
DOI https://dx.doi.org/10.2174/1381612819999131218175905 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-Tumor Efficacy of Pyrvinium Pamoate Nanoliposomes in an Experimental Model of Melanoma
Anti-Cancer Agents in Medicinal Chemistry Isoform-Selective PI3K Inhibitors for Various Diseases
Current Topics in Medicinal Chemistry Restoration of Antitumor Immunity Through Selective Inhibition of Myeloid Derived Suppressor Cells by Anticancer Therapies
Current Molecular Medicine PfRIO-2 Kinase is a Potential Therapeutic Target of Antimalarial Protein Kinase Inhibitors
Current Drug Discovery Technologies Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies
Anti-Cancer Agents in Medicinal Chemistry A Comprehensive Review of Poorly Differentiated Neuroendocrine Carcinomas (pdNECs): a Niche to Find Novel Opportunities
Current Pharmaceutical Design QSAR Study of Androstenedione Analogs as Aromatase Inhibitors
Letters in Drug Design & Discovery Development of a High Throughput Drug Screening Assay for the Detection of Changes in Tau Levels - Proof of Concept with HSP90 inhibitors
Current Alzheimer Research Kisspeptin: Paving the Way to a New Therapeutic Avenue in Reproduction
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Foods for Health and to Treat Diseases
Current Pediatric Reviews 3D-QSAR and Docking Simulation Studies of Some Benzopyrone Derivatives as Inhibitors for Breast Cancer Stem Cell Growth via PGlycoprotein Mediated Efflux
Current Bioinformatics The Impact of the Emerging Genomics Data on the Management of Agerelated Phenotypes in the Context of Cellular Senescence
Current Drug Targets Identification of Molecular Targets Associated with Ethanol Toxicity and Implications in Drug Development
Current Pharmaceutical Design Xenobiotic Sulphation and its Variability During Inflammation: a Factor in Adverse Drug Reactions?
Current Drug Metabolism Mammaglobin-Based Strategies for Treatment of Breast Cancer
Current Cancer Drug Targets Molecular Docking Studies of the Antitumoral Activity and Characterization of New Chalcone
Current Topics in Medicinal Chemistry DNA Demethylation by TET Proteins: A Potential Therapeutic Target in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Between Bench and Bed Side: PI3K Inhibitors
Current Molecular Pharmacology Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design Fractalkine/CX3CR1 Signalling in Chronic Pain and Inflammation
Current Pharmaceutical Biotechnology